Tophus burden reduction with pegloticase: Results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Arthritis Research and Therapy

Volumn 15, Issue 5, 2013, Pages

  Baraf, Herbert S B ^a   Becker, Michael A ^b   Gutierrez Urena, Sergio R ^c   Treadwell, Edward L ^d   Vazquez Mellado, Janitzia ^e   Rehrig, Claudia D ^f   Ottery, Faith D ^g   Sundy, John S ^h   Yood, Robert A ⁱ  

^a Center for Rheumatology and Bone Research   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^d EAST CAROLINA UNIVERSITY   (United States)

^e HOSPITAL GENERAL DE MÉXICO   (Mexico)

^f Savient Pharmaceuticals Inc   (United States)

^g Formerly of Savient Pharmaceuticals Inc   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Reliant Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGLOTICASE; PLACEBO; URIC ACID; ALLOPURINOL; ANTIGOUT AGENT; MACROGOL DERIVATIVE; URATE OXIDASE;

ADULT; ARTHROPATHY; ARTICLE; CHRONIC ARTHRITIS; CONTROLLED STUDY; DIGITAL IMAGING; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; TOPHUS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; AGED; BLOOD; CHRONIC DISEASE; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ALLOPURINOL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TIME FACTORS; TREATMENT OUTCOME; URATE OXIDASE; URIC ACID;

EID: 84884541848     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4318     Document Type: Article

References (35)

1. Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, Edwards L, Kawata AK, Frank L, Waltrip R, Maroli A, Huang B, Sundy JS, Gout Natural History Study Group Quality of life and disability in patients with treatment-failure gout. J Rheumatol 2009, 36:1041-1048. 10.3899/jrheum.071229, 19332629, Gout Natural History Study Group.
2. Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW, Maroli AN, Horowitz Z, Pegloticase Phase 2 Study Investigators Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008, 58:2882-2891. 10.1002/art.23810, 18759308, Pegloticase Phase 2 Study Investigators.
3. Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes 2012, 10:117. 10.1186/1477-7525-10-117, 3499162, 22999027.
4. Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A. Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 2009, 48:582-586.
5. Yu KH, Luo SF, Liou LB, Wu YJ, Tsai WP, Chen JY, Ho HH. Concomitant septic and gouty arthritis-an analysis of 30 cases. Rheumatology (Oxford) 2003, 42:1062-1066.
6. Chen J, Chinthrajah S, Aronowitz P. Severe tophaceous gout. J Hosp Med 2007, 2:194. 10.1002/jhm.225, 17551953.
7. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 2007, 46:1804-1807.
8. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003, 349:1647-1655. 10.1056/NEJMcp030733, 14573737.
9. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 2008, 75:S5-S8.
10. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324. 10.1136/ard.2006.055269, 1798308, 16707532, EULAR Standing Committee for International Clinical Studies Including Therapeutics.
11. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356-360. 10.1002/art.10511, 12209479.
12. Hershfield MS. Reassessing serum urate targets in the management of refractory gout: can you go too low?. Curr Opin Rheumatol 2009, 21:138-142. 10.1097/BOR.0b013e3283257b83, 2920449, 19339924.
13. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009, 36:1273-1282. 10.3899/jrheum.080814, 19286847.
14. Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009, 48:188-194.
15. Baraf HS, Matsumoto AK, Maroli AN, Waltrip RW. Resolution of gouty tophi after twelve weeks of pegloticase treatment. Arthritis Rheum 2008, 58:3632-3634. 10.1002/art.23993, 18975338.
16. Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW, Hamburger SA, Becker MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011, 306:711-720.
17. Maroli AN, Waltrip R, Alton M, Baraf HSB, Huang B, Rehrig C, Ford R. First application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout [abstract]. Arthritis Rheum 2009, 60:1111. doi:10.1002/art.26186.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubenstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
19. Schumacher HR, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005, 32:2368-2372.
20. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007, 34:1888-1893.
21. Gerster JC, Landry M, Dufresne L, Meuwly JY. Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis 2002, 61:52-54. 10.1136/ard.61.1.52, 1753862, 11779759.
22. Popp JD, Bidgood WD, Edwards NL. Magnetic resonance imaging of tophaceous gout in the hands and wrists. Semin Arthritis Rheum 1996, 25:282-289. 10.1016/S0049-0172(96)80038-2, 8834016.
23. Yu JS, Chung C, Recht M, Dailiana T, Jurdi R. MR imaging of tophaceous gout. AJR Am J Roentgenol 1997, 168:523-527. 10.2214/ajr.168.2.9016240, 9016240.
24. Schumacher HR, Becker MA, Edwards NL, Palmer WE, MacDonald PA, Palo W. Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract 2006, 60:408-414. 10.1111/j.1368-5031.2006.00853.x, 16620352.
25. Gerster JC, Landry M, Rivier G. Computed tomographic imaging of subcutaneous gouty tophi. Clin Rheumatol 1998, 17:62-64. 10.1007/BF01450961, 9586682.
26. Dalbeth N, Clark B, Gregory K, Gamble GD, Doyle A, McQueen FM. Computed tomography measurement of tophus volume: comparison with physical measurement. Arthritis Rheum 2007, 57:461-465. 10.1002/art.22612, 17394233.
27. Johnson TR, Weckbach S, Kellner H, Reiser MF, Becker CR. Clinical image: dual-energy computed tomographic molecular imaging of gout. Arthritis Rheum 2007, 56:2809. 10.1002/art.22803, 17665437.
28. Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, Nicolaou S. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009, 68:1609-1612. 10.1136/ard.2008.099713, 19066180.
29. Dalbeth N, Schauer C, Macdonald P, Perez-Ruiz F, Schumacher HR, Hamburger S, Choi HK, McQueen FM, Doyle A, Taylor WJ. Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Ann Rheum Dis 2011, 70:597-604. 10.1136/ard.2010.139899, 21216814.
30. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005, 353:2450-2461. 10.1056/NEJMoa050373, 16339094.
31. Wallace SL, Robinson H, Masi AT, Decker JL, McCarthy DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900. 10.1002/art.1780200320, 856219.
32. Richette P, Brière C, Hoenen-Clavert V, Loeuille D, Bardin T. Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 2007, 34:2093-2098.
33. Erwin CL, Nancollas GH. The crystallization and dissolution of sodium urate. J Crystal Growth 1981, 53:215-223.
34. Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 2010, 30:495-503. 10.1007/s00296-009-1002-8, 19543895.
35. Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis 2013, 72:1469-1474. 10.1136/annrheumdis-2012-201795, 3756467, 23144450.